Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium Read More
MammaPrint is the only FDA-cleared gene expression test to identify Read More
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to Read More
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- Read More
Data show MammaPrint® is the first and most comprehensive FDA-cleared test Read More
Data demonstrate Research Use Only ImPrint test’s ability to identify Read More
Company to present multiple recent Registry sub-studies driving cancer care Read More
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
Strategic hire underscores commitment to commercial growth across genomic assay Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
© 2022 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
